TY - JOUR
T1 - The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum
AU - Alzheimers Dis Neuroimaging Initia
AU - Parelsnoer Inst Neurodegenerative
AU - Banning, Leonie C. P.
AU - Ramakers, Inez H. G. B.
AU - Koehler, Sebastian
AU - Bron, Esther E.
AU - Verhey, Frans R. J.
AU - de Deyn, Peter Paul
AU - Claassen, Jurgen A. H. R.
AU - Koek, Huiberdina L.
AU - Middelkoop, Huub A. M.
AU - van der Flier, Wiesje M.
AU - van der Lugt, Aad
AU - Aalten, Pauline
PY - 2020/7
Y1 - 2020/7
N2 - Objectiv(e): To investigate the relationship between Alzheimer's disease biomarkers and neuropsychiatric symptoms. Methods: Data from two large cohort studies, the Dutch Parelsnoer Institute - Neurodegenerative Diseases and the Alzheimer's Disease Neuroimaging Initiative was used, including subjects with subjective cognitive decline (N= 650), mild cognitive impairment (N = 887), and Alzheimer's disease dementia (N = 626). Cerebrospinal fluid (CSF) levels of A beta(42), t-tau, p-tau, and hippocampal volume were associated with neuropsychiatric symptoms (measured with the Neuropsychiatric Inventory) using multiple logistic regression analyses. The effect of the Mini-Mental State Examination (as proxy for cognitive functioning) on these relationships was assessed with mediation analyses. Results: Alzheimer's disease biomarkers were not associated with depression, agitation, irritability, and sleep disturbances. Lower levels of CSF A beta(42), higher levels of t- and p-tau were associated with presence of anxiety. Lower levels of CSF A beta(42) and smaller hippocampal volumes were associated with presence of apathy. All associations were mediated by cognitive functioning. Conclusion: The association between Alzheimer's disease pathology and anxiety and apathy is partly due to impairment in cognitive functioning.
AB - Objectiv(e): To investigate the relationship between Alzheimer's disease biomarkers and neuropsychiatric symptoms. Methods: Data from two large cohort studies, the Dutch Parelsnoer Institute - Neurodegenerative Diseases and the Alzheimer's Disease Neuroimaging Initiative was used, including subjects with subjective cognitive decline (N= 650), mild cognitive impairment (N = 887), and Alzheimer's disease dementia (N = 626). Cerebrospinal fluid (CSF) levels of A beta(42), t-tau, p-tau, and hippocampal volume were associated with neuropsychiatric symptoms (measured with the Neuropsychiatric Inventory) using multiple logistic regression analyses. The effect of the Mini-Mental State Examination (as proxy for cognitive functioning) on these relationships was assessed with mediation analyses. Results: Alzheimer's disease biomarkers were not associated with depression, agitation, irritability, and sleep disturbances. Lower levels of CSF A beta(42), higher levels of t- and p-tau were associated with presence of anxiety. Lower levels of CSF A beta(42) and smaller hippocampal volumes were associated with presence of apathy. All associations were mediated by cognitive functioning. Conclusion: The association between Alzheimer's disease pathology and anxiety and apathy is partly due to impairment in cognitive functioning.
KW - Neuropsychiatric symptoms
KW - biomarkers
KW - neurocognitive disorders
KW - mild cognitive impairment
KW - Alzheimer's disease dementia
KW - MILD COGNITIVE IMPAIRMENT
KW - CEREBROSPINAL-FLUID BIOMARKERS
KW - CSF BIOMARKERS
KW - DEPRESSIVE SYMPTOMS
KW - EARLY-STAGE
KW - MRI
KW - PREVALENCE
KW - PROGRESSION
KW - MODERATORS
KW - MEDIATORS
U2 - 10.1016/j.jagp.2020.01.012
DO - 10.1016/j.jagp.2020.01.012
M3 - Article
SN - 1064-7481
VL - 28
SP - 735
EP - 744
JO - American Journal of Geriatric Psychiatry
JF - American Journal of Geriatric Psychiatry
IS - 7
ER -